Investigating the Effects of Different Incision Types on Aesthetic Outcomes and Incision-related Complications After Breast Reconstruction Surgery
Launched by HUBEI CANCER HOSPITAL · Feb 12, 2024
Trial Information
Current as of June 27, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
No description provided
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • 1. total mastectomy
- • 2. implant and/or autologous breast reconstruction.
- Exclusion Criteria:
- • 1. No total mastectomy
- • 2. loss of data or loss of follow-up
- • 3. fatal cases
About Hubei Cancer Hospital
Hubei Cancer Hospital is a leading medical institution dedicated to cancer research, treatment, and patient care, located in Wuhan, China. As a prominent clinical trial sponsor, the hospital is committed to advancing oncology through rigorous scientific investigation and innovative therapeutic approaches. With a multidisciplinary team of experienced oncologists, researchers, and healthcare professionals, Hubei Cancer Hospital aims to improve patient outcomes by facilitating groundbreaking clinical trials that explore new treatment modalities and enhance understanding of cancer biology. The institution prioritizes patient safety and ethical standards, ensuring that all trials are conducted in accordance with regulatory guidelines and best practices in clinical research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Wuhan, Hongshan District, China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported